Matt Zeller, country president of Novartis Australia and New Zealand, said, “The impact of CVD in Australia is devastating, claiming one life every 12 minutes. Now, Leqvio is available on the PBS and this first-in-class treatment option has the potential to transform patient care and help improve the lives of individuals living with CVD.” …
Novartis welcomes the listing of first-in-class cholesterol-lowering therapy
April 2, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
Roche announces historic investment to build US manufacturing base
April 23, 2025 - - Latest News -
'Reflecting the experience of people living with cancer, Pfizer’s new campaign Part of the Story seeks to reshape the narrative'
April 23, 2025 - - Latest News -
US trade agenda looks mostly disinterested in pharmaceuticals
April 23, 2025 - - Latest News -
Mesoblast says Ryoncil payer coverage extended to over 100 million Americans
April 22, 2025 - - Australian Biotech -
Anatara provides update following completion of analysis of Phase 2 GaRP-IBS clinical trial
April 22, 2025 - - Australian Biotech -
Recce Phase 2 trial receives additional approval for treating diabetic patients with topical gel
April 22, 2025 - - Australian Biotech -
Race says patient enrolment opened at second site for RC220 solid tumour trial
April 22, 2025 - - Australian Biotech